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The fact that certain ultraviolet (UV) ﬁlters used in cosmetics
display estrogenic activity prompted us to study potential actions
on androgen receptors (AR) in the human breast carcinoma cell
line MDA-kb2, which expresses functional endogenous AR and
glucocorticoid receptors (GR) and is stably transfected with a
luciferase reporter plasmid. Dihydrotestosterone (DHT), methyl-
trienolone (R1881), methyltestosterone, danazol, and andro-
stenedione increased luciferase activity, with EC50 values between
0.11 nM (R1881), 0.14 nM (DHT), and 73.5 nM (androstenedione).
DHT-induced luciferase gene expression was inhibited by nonste-
roidal antiandrogens, hydroxyﬂutamide, ﬂutamide, bicalutamide,
and vinclozolin. In contrast, the steroidal AR agonist/antagonist
cyproterone actetate showed agonistic activity in the absence and
presence of DHT, which was not blocked by hydroxyﬂutamide and
thus seems not to be mediated by AR. GR-mediated activation of
luciferase by dexamethasone was 100 times less potent than DHT
and was not antagonized by hydroxyﬂutamide. The cell line was
used for screening of UV ﬁlters, benzophenone–3 (Bp-3), benzo-
phenone–4, 3-benzylidene camphor, 4-methylbenzylidene cam-
phor, butyl-methoxy-dibenzoylmethane, homosalate (HMS), octyl-
dimethyl-PABA, and octyl-methoxycinnamate. Two of these, Bp-3
and HMS, antagonized DHT-induced AR activation below cyto-
toxic concentrations, with IC50 of 5.57 10
–6 M (HMS) and 4.98 10–6
M (Bp-3). None of the eight UV ﬁlters displayed agonistic activity
when tested alone, but high concentrations of Bp-3 induced an
increase of luciferase activity in the presence of dexamethasone,
which was not blocked by hydroxyﬂutamide or the estrogen an-
tagonist, ICI 182,780. These data indicate that the UV ﬁlters Bp-3
and HMS possess antiandrogenic activity in vitro in addition to
estrogenic activity.
Key Words: MDA-kb2 cells; androgen receptor; androgen; anti-
androgen; endocrine disruptor; pesticide; UV ﬁlter.
The presence in the environment of increasing amounts of
synthetic chemicals is causing concern about unknown long-
term toxicities, especially the possibility of interference with
endocrine systems (IPCS, 2002; Kelce et al., 1998). We pre-
viously identiﬁed estrogenic activity in several ultraviolet (UV)
ﬁlters in vitro and in vivo (Schlumpf et al., 2001). This
prompted us to initiate a study on their potential interaction
with androgen receptors. UV ﬁlters are added to sunscreen
products in continuously higher amounts, since sun protection
factors (SPF) increased from SPF 1–2 in 1950 to SPF 40–60
today (SPF  ratio of UV light dose producing minimal
erythema in the protected skin versus the unprotected skin). In
addition, UV ﬁlters are also included in cosmetics for product
protection and stability. These persistent chemicals have been
detected in ﬁsh (Nagtegaal et al., 1997) and in human milk (Hany
and Nagel, 1997). Interactions of xenobiotics with androgens may
cause developmental abnormalities, as shown following the ex-
posure to the antiandrogenic pesticides vinclozolin, procymidone,
or linuron (Kelce et al., 1994, 1997; Lambright et al., 2000; Ostby
et al., 1999). As there is 100% sequence homology between rat
and human AR ligand binding domains, analogous effects can be
expected to be mediated by human AR (Kelce et al., 1998).
In this study, we validated the human AR expressing cell
line MDA-kb2 with known androgens and antiandrogens and
used the system to test UV ﬁlters for androgenic or antiandro-
genic activity in vitro. Eight of the most frequently used
compounds were chosen among the total of 30 UV ﬁlters
admitted for use in Switzerland. The human breast carcinoma
cell line, MDA-kb2, expresses high levels of functional endog-
enous androgen receptor (AR) and also glucocorticoid receptor
(GR), while estrogen receptor alpha and progesterone receptor
are not detectable at the RNA level, and estrogen receptor beta
is expressed only at low levels (Hall et al., 1992). The cells are
stably transfected with a luciferase transporter plasmid driven
by the mouse mammary tumor virus promoter (MMTV) that
can be activated through both AR and GR (Wilson et al.,
2002). Compounds acting through AR or GR can therefore
induce luciferase expression. It was shown earlier that known
AR antagonists like hydroxyﬂutamide, the vinclozolin metab-
olites M1 and M2, p,pDDE, and linuron-inhibited dihydrotes-
tosterone (DHT)-induced gene expression in this cell line (Wil-
son et al., 2002).
MATERIALS AND METHODS
Chemicals. Methyltrienolone (R1881, also called metribolone) (CAS no.
965-93-5) was purchased from NEN™ (NEN™ Life Science Products, Inc.,
1 To whom correspondence should be addressed at Institute of Pharmacol-
ogy and Toxicology, University of Zurich, Winterthurerstrasse 190, CH-8057,
Zurich, Switzerland. Fax: 41 (1) 635-6857. E-mail: schlumpm@
pharma.unizh.ch.
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Boston, MA 02118). 5-dihydrotestosterone (DHT) (CAS no. 521-18-6, pu-
rity  99.0%), methyltestosterone (Met-T) (CAS no. 58-18-4, purity 
97.0%), androstenedione (CAS no. 63-05-8, purity  98.0%), and dexameth-
asone (DEX) (CAS no. 50-02-2, purity  97.0%) were obtained from Fluka
(Fluka Chemie Gmbh CH-9471 Buchs, Switzerland), danazol (CAS no. 17230-
88-5, purity  98.0%), ﬂutamide (CAS no. 13311-84-7, purity  99%), and
cyproterone acetate (CAS no. 427-51-0, purity  98.0%) from Sigma (Sigma-
Aldrich Chemie GmbH, Schnelldorf, Germany), vinclozolin (CAS no. 50471-
44-8, purity  99.4%) from Riedel de Haen (Rdh Laborchemikalien GmbH &
Co. KG D-30918 Seelze). Bicalutamide (Casodex, ICI176.334) was a gift from
Dr. W. Ko¨rner (Bayerisches Landesamt fu¨r Umweltschutz, D-86179 Augs-
burg, Germany). Hydroxyﬂutamide (OHF) was obtained from Schering-
Plough Research Inst., Kenilworth, NJ 07033). The UV screens 3-(4-methyl-
benzylidene) camphor (4-MBC, Eusolex 6300) (CAS no. 36861-47-9 
99.7%), 2-ethylhexyl-4-dimethylamino-benzoate (OD-PABA, Eusolex 6007
 98.5%) (CAS no. 21245-02-3), 4-tert-butyl-4-methoxy-dibenzoylmethane
(B-MDM, Eusolex 9020) (CAS no. 70356-09-1  98%), 2-ethylhexyl-4-
methoxycinnamate (OMC, Eusolex 2292) (CAS no. 5466-77-3  98%), 2-hy-
droxy-4-methoxybenzophenone (Benzophenone-3, Bp-3, Eusolex 4360) (CAS
no. 131-57-7  99%), 3,3,5-trimethylcyclohexyl salicylate (Homosalate,
HMS, Eusolex HMS) (CAS no. 118-56-9  98%), and 3-benzylidencamphor
(3-BC) (CAS no. 15087-24-8  99.9%) were purchased from Merck (Di-
etikon, Switzerland), 2-benzoyl-5-methoxy-1-phenol-4-sulfonic acid (Benzo-
phenone 4, Bp-4) (CAS no. 4065-45-6, purity  97.0) from Fluka (Fluka
Chemie Gmbh, CH-9471 Buchs, Switzerland).
Stock solutions of the compounds were prepared in absolute ethanol at a
concentration of 10–2 M, stored at –20°C, and diluted to desired concentrations
in L-15 (LEIBOVITZ) medium (Gibco, Cat No. 11415–049, Lot No.
3041839). The ﬁnal ethanol concentrations in the medium did not exceed 1%
(v/v). This concentration did not affect cell proliferation (Schlumpf et al.,
2001).
Cell line and cell culture conditions. The MDA-kb2 cell line was kindly
provided by K. Bobseine and L. E. Gray (Endocrinology Branch, U.S. EPA,
Research Triangle Park, NC). For routine maintenance, cells were grown in
25-cm2 canted neck tissue culture plastic ﬂasks (Falcon, Oxnard, CA) in
Leibovitz’s L-15 medium at 37°C in a humidiﬁed incubator under regular
atmospheric conditions (no CO2). The medium was supplemented with 10%
heat-inactivated (56°C, 30 min) fetal bovine serum (FBS, Lot No. 1077868,
Cat No. 16000–044, Life & Technologies, GIBCo, Grand Island, NY), and 1%
(v/v) (ﬁnal concentration) antibiotic-antimycotic agent (Gibcobrl, Cat No.
15240–062, Lot No. 1078238).
AR-mediated gene-reporter activation assay in MDA-kb2 cells. Tests
were carried out according to the protocol of Wilson et al. (2002) with several
modiﬁcations. MDA-kb2 cells were trypsinized and seeded into 96-well plates
(Costar NY, USA) at a density of about 1  104 cells/well with 100 l
media/well using a multichannel pipettor. After the cells had attached, medium
was removed and replaced by dosing medium. For every experiment, wells in
column no. 6 were ﬁlled with medium as negative control, wells in column no.
7 with 1% ethanol in medium as solvent control, wells in column no. 12 with
10 nM DHT as a positive control (0.1 or 0.5 nM for testing AR antagonists),
and wells in column no. 1 with 1M ﬂutamide or bicalutamide alone (for
comparison with the test chemical alone). Wells in columns no. 2–5 and 8–11
were ﬁlled with different concentrations of the test chemical, rows 1–4
FIG. 1. Androgen receptor (AR)-mediated reporter gene activation in-
duced by androgen agonists in MDA-kb2 cells. Mean  SEM of ﬁve inde-
pendent experiments. Ethanol concentrations (v/v): from 1:1010 to 1:103. Filled
circle, DHT; open circle, R1881; ﬁlled diamond, Met-T; ﬁlled upward-pointing
triangle, danazol; ﬁlled downward-pointing triangle, androstenedione.
TABLE 1
Potency of Androgen Receptor and Glucocorticoid Receptor Agonists in the MDA-Kb2 Cell Transcriptional Activation Assay
Chemicals
EC50 (M)a
Agonists alone
Agonists 
1 M ﬂutamide
Agonists 
1 M hydroxyﬂutamide Relative androgenic potencya,b (%) M
DHT 1.36  0.17  10–10 4.22  0.32  10–10* 5.11  1.33  10–9** 100
R1881 1.11  0.09  10–10 3.89  0.32  10–10* 128.99  22.53
Met-T 1.25  0.32  10–9 3.09  1.20  10–9 1.25  0.11  10–8** 11.28  1.30
Danazol 5.55 0.52  10–9 1.66  0.19  10–8 * 7.48  0.43  10–8** 2.41  0.26
Androstenedione 7.35 1.33  10–8 1.69  0.24  10–7 * 2.35  0.63  10–6** 0.21  0.03
Dexamethasone 1.26 0.14  10–8 1.23  0.18  10–8 1.29  0.23  10–8
aMean  SEM of ﬁve independent experiments.
bRAP 
EC50(DHT)
EC50(test compound) 100.
* and **, different from agonists alone for p  0.05 and p  0.01, respectively.
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together with DHT and rows 5–8 without DHT. Cells were incubated over-
night at 37°C.
For measuring luciferase activity, medium was removed. Cells were washed
gently two times with Dulbecco’s phosphate-buffered saline (PBS) at room
temperature. Lysis Buffer (Promega, Cat No. E1351, Lot No. 119684) was
added (25 l/well), and cells were left at room temperature for 30 min. The
contents of the wells (25 l/well) were transferred onto a white Dynatech
microtiter plate (DYNEX Technologies, Inc., Chantilly, VA). The plate was
read in a luminometer ML 1000 [Dynatech Laboratories, Chantilly, VA], with
injection set to deliver 25 l 1 mM D-luciferin and 25 l reaction buffer (25
mM glycylglycine, 15 mM MgCl2, 5 mM ATP, 0.1 mg/ml BSA, pH 7.8) using
a ﬂash-detection program.
MTT reduction assay. Cytotoxicity was estimated with the MTT [3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] dye reduction assay
as described by Mosmann (1983), with some modiﬁcations. Brieﬂy, cells were
seeded at 10,000 cells/100 l into 96-well ﬂat-bottom culture plates, grown for
24 h, and then treated with the chemicals at the indicated concentrations and
time intervals. After incubation with chemicals, 0.1 mg (20 l/well of 5 mg/ml
in PBS) MTT was added. Plates were further incubated for 4 h at 37°C. The
medium was then discarded, 100 l of DMSO was added to each well to
FIG. 2. Effects of androgen receptor
antagonists in MDA-kb2 cells. Data are
expressed as mean  SEM. Open circle,
antagonist alone; ﬁlled square, antagonist
in presence of 0.5 nM DHT; ﬁlled circle,
antagonist in presence of 0.1 nM DHT;
open upward-pointing triangle, 0.5 nM
DHT; open downward-pointing triangle,
0.1 nM DHT. * and ** signiﬁcant differ-
ence (p  0.05 and p  0.01) as com-
pared to activation by 0.1 or 0.5 nM
DHT, respectively. Ethanol concentra-
tions (v/v): from 1:108 to 1:103.
TABLE 2
Antiandrogenic Potency of Antiandrogens and UV Filters in
MDA-kb2 Cells
Chemicalsa
IC50
(in 0.5 nM DHT) (M)b
IC50
(in 0.1 nM DHT) (M)2
Hydroxyﬂutamide 2.54  0.09  10–7 (4) 3.45  0.20  10–8 (4)
Flutamide 3.62 0.19  10–6 (4) 7.88  1.05  10–7 (6)
Bicalutamide 8.30 0.46  10–8 (4) 3.84  1.44  10–7 (5)
Vinclozolin 7.92 2.13  10–7 (5) 1.09  0.14  10–7 (5)
Bp-3 2.85  1.18  10–5 (6) 4.98  0.64  10–6 (6)
HMS 1.31  0.51  10–5 (6) 5.57  0.54  10–6 (6)
Note. Inactive UV ﬁlters (Fig. 5): Bp-4, 3-BC, 4-MBC, B-MDM, OD-
PABA, OMC.
aChemicals: Bp-3: benzophenone-3; HMS: homosalate; Bp-4: benzophe-
none 4; 3-BC: 3-benzylidenecamphor; 4-MBC: 3-(4-methylbenzylidene) cam-
phor; B-MDM: 4-tert-butyl-4-methoxy-dibenzoylmethane; OD-PABA: 2-eth-
ylhexyl-4-dimethylamino-benzoate; OMC: 2-ethylhexyl-4-methoxycinnamate.
bMean  SEM and number of independent experiments.
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dissolve the formazan crystals formed, and the plate was agitated for 1 min.
Absorption at 540 nm (reference ﬁlter 620 nm) was quantiﬁed with a micro-
plate reader (Anthos labtec reader). MTT-reduction for each treatment was
expressed as a percentage of control values.
Data analysis. Results were expressed as mean fold induction compared to
negative control (medium)  SE of the mean (SEM). Luciferase activities of
negative control and solvent control were identical. Data were analysed by
two-way ANOVA followed by Bonferroni pairwise comparisons (SYSTAT
5.01 software). Differences between groups were considered statistically sig-
niﬁcant at p  0.05.
Nonlinear regression and calculation of EC50 and IC50 values were per-
formed with GraphPad Prism 2.01 (GraphPad Software, Inc., San Diego, CA
92121). Mean EC50 or IC50 values of compounds were calculated from the EC50
or IC50 values of individual experiments.
EC50 is the concentration of the agonist producing 50% maximal induction
of luciferase activity in MDA-kb2 cells, whereas, IC50 is the concentration of
the antagonist producing 50% inhibition of agonist-induced luciferase activity
in the cells.
RESULTS
Validation of the MDA-kb2 Cell Assay: Androgen Receptor
Agonists
MDA-kb2 cells were exposed to known androgenic chemi-
cals, 5-dihydrotestosterone (DHT), methyltrienolone (R1881,
metribolone), methyltestosterone (Met-T), danazol, and andro-
stenedione. The ﬁve androgens increased luciferase activity of
MDA-kb2 cells in a concentration-dependent manner (Fig. 1).
DHT and R1881 induced luciferase expression signiﬁcantly
from 0.06 nM and 0.03 nM, respectively (compared with
negative control p 0.05). The rank order of EC50 and relative
androgenic potency values corresponded to the known poten-
cies of the chemicals (Table 1) (Foster and Cunha, 1999; Wiita
et al., 1995).
Effect of Androgen Antagonists on DHT-Induced AR
Activation
Nonsteroidal AR antagonists. When administered alone,
ﬂutamide, bicalutamide, and the pesticide vinclozolin did not
show a detectable effect on luciferase activity in MDA-kb2
cells (Fig. 2). Hydroxyﬂutamide induced luciferase activity at
the highest concentration tested (10 M) in the absence or
presence of DHT. All four compounds antagonized luciferase
activation by 0.1 or 0.5 nM DHT in a concentration-dependent
FIG. 3. (A) Effect of cyproterone
acetate (CPA) on luciferase activity of
MDA-kb2 cells in the presence or ab-
sence of 0.1 nM DHT. Open circle, CPA
in presence of 0.1 nM DHT; ﬁlled circle,
CPA alone; open downward-pointing tri-
angle, 0.1 nM DHT. Mean  SEM of
four independent experiments. **Signif-
icant difference from negative control
(p  0.01). Signiﬁcant difference
(p  0.01) as compared to activation by
0.1 nM DHT alone. Ethanol concentra-
tions (v/v): from 1 : 107 to 1 : 103. (B)
Effect of hydroxyﬂutamide on luciferase
activity of MDA-kb2 cells in the pres-
ence of 1 M CPA. Mean  SEM of
three independent experiments. Open cir-
cle, 1 M CPA; ﬁlled circle, hydroxyﬂu-
tamide in presence of 1 M CPA. Ethanol
concentration (v/v): from 1:107 to 1:103.
FIG. 4. Effect of dexamethasone on luciferase activity in MDA-kb2 cells
in the absence and presence of 1 M ﬂutamide and 1 M hydroxyﬂutamide.
Mean  SEM of ﬁve independent experiments. Filled circle, dexamethasone;
open circle, dexamethasone in presence of 1 M ﬂutamide; open triangle,
dexamethasone in presence of 1 M hydroxyﬂutamide. **Dexamethasone
without ﬂutamide and hydroxyﬂutamide, signiﬁcant difference from negative
control (p  0.01). Ethanol concentrations (v/v): from 1:109 to 1:104.
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manner. IC50 values are shown in Table 2. The effect of
hydroxyﬂutamide was signiﬁcant at and above concentrations
of 0.01 M or 0.06 M (Fig. 2A).
Cyproterone acetate. In contrast to the nonsteroidal AR
antagonists, cyproterone acetate (CPA) increased luciferase
activity dose-dependently in MDA-kb2 cells when given alone
(Fig. 3A). The effect of DHT (0.1 nM) on luciferase activity
seemed almost unchanged by low concentrations of CPA; the
slight reduction at around 100 nM CPA is statistically not
signiﬁcant. At concentrations above 1 M, CPA increased
luciferase activity to the same extent as in the absence of DHT
(Fig. 3A). The agonistic effect of 1 M CPA was not inhibited
by hydroxyﬂutamide (Fig. 3B).
Glucocorticoid Receptor (GR) Agonist-Induced Luciferase
Activation
Since MDA-kb2 cells contain both endogenous AR and GR,
compounds that act through either receptor could activate the
luciferase reporter. Dexamethasone (DEX) increased luciferase
expression in MDA-kb2 cells in a concentration-dependent
manner (Fig. 4), with a signiﬁcant effect at 5 nM and above
(compared with negative control p  0.01). The EC50 of
FIG. 5. Antagonism by the UV ﬁl-
ters benzophenone-3 (Bp-3) (A) and ho-
mosalate (HMS) (B) of DHT (0.1 nM or
0.5 nM)-induced androgen receptor (AR)
activation in MDA-kb2 cells and absence
of antagonism by other six UV ﬁlters (C
and D). Mean SEM of six independent
experiments. ** signiﬁcant difference vs.
0.1 nM or 0.5 nM DHT (p  0.01).
Ethanol concentrations (v/v): from 1:106
to 1:102.
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dexamethasone, 12.6  1.38 nM, was about 100 times higher
than that of DHT.
Differentiation between AR and GR agonists. When AR
and GR agonists were tested in the presence of 1 M ﬂutamide
or 1 M hydroxyﬂutamide, both compounds antagonized the
increase in luciferase activity induced by androgens, but
showed no antagonism against dexamethasone (Table 1, Fig. 4).
Screening of UV Filters for Androgenic or Antiandrogenic
Activity
In order to assess possible agonistic or antagonistic actions
of UV ﬁlters on AR in MDA-kb2 cells, the cells were exposed
to eight UV ﬁlters in the absence or presence of 0.1 or 0.5 nM
DHT. The list of test chemicals included 4-MBC, 3-BC, OD-
PABA, B-MDM, OMC, Bp-3, Bp-4, and HMS. None of the
compounds displayed agonistic activity (Fig. 5). However, two
UV-ﬁlters, Bp-3 and HMS, reduced DHT-induced AR activa-
tion in MDA-kb2 cells in a concentration-dependent manner
(Figs. 5A and 5B; Table 2). As indicated by the MTT reduction
assay, this effect was not due to cytotoxicity, which was seen
only at and above 200M (Fig. 6). 4-MBC, 3-BC, OD-PABA,
B-MDM, Bp-4, and OMC did not inhibit AR activation by
DHT across a wide concentration range (Figs. 5C and 5D).
Bp-3 and HMS were also tested with respect to possible
interactions with GR activation (Fig. 7). HMS did not change
the effect of 50 nM dexamethasone on luciferase activity. High
concentrations of Bp-3 induced a small increase in luciferase
activity beyond the level produced by dexamethasone alone.
FIG. 6. Concentration-response curves for effects of Bp-3 and HMS on
MTT reduction in MDA-kb2 cells. Mean  SEM of four independent exper-
iments. * and **, signiﬁcantly lower than control (p  0.05 and p  0.01).
FIG. 7. (A) Effect of Bp-3 and HMS on luciferase activity in MDA-kb2 cells in the presence of 50 mM dexamethasone. Mean  SEM of ﬁve independent
experiments. Ethanol concentrations (v/v): from 1 : 106 to 1 : 102. (B) Effect of Bp-3 on luciferase activity in MDA-kb2 cells in the presence of 50 nM
dexamethasone and 1 M ICI 182, 780. Mean  SEM of ﬁve independent experiments. **Signiﬁcant difference vs. 50 nM dexamethasone and 1 M ICI 182,
780 (p  0.01). Ethanol concentrations (v/v): from 1:106 to 1:102. (C) Effect of Bp-3 on luciferase activity in MDA-kb2 cells in the presence of 50 nM
dexamethasone  1 M hydroxyﬂutamide. Mean  SEM of ﬁve independent experiments. * and **: signiﬁcant difference vs. 50 nM dexamethasone  1 M
hydroxyﬂutamide (p  0.05 and p  0.01). Ethanol concentrations (v/v): from 1:106 to 1:102.
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This effect was not prevented either by the estrogen antagonist
ICI 182,780 nor by hydroxyﬂutamide (Fig. 7B,C).
DISCUSSION
MDA-kb2 cells represent a cell line that expresses both
endogenous human AR and GR and has been stably transfected
by Kathy Bobseine with the MMTV-luciferase gene (Wilson et
al., 2002). In our validation experiments, AR agonists [5-
dihydrotestosterone (DHT), methyltrienolone (R1881, metri-
bolone), methyltestosterone, androstenedione, and danazol]
displayed EC50 values and relative androgenic potencies cor-
responding to the potency range reported in earlier studies
(Foster and Cunha, 1999; Wiita et al., 1995). A distinction
between AR and GR agonists can be achieved with androgen
antagonists such as hydroxyﬂutamide, which antagonized the
effect of DHT on luciferase expression without concomitant
antagonism of dexamethasone. These results are comparable to
ﬁndings of Wilson et al. (2002). The data indicate that the cell
line represents a sensitive tool for the screening of AR ago-
nists.
The assay likewise proved to be suitable and sensitive for the
detection of AR antagonistic effects of nonsteroidal antiandro-
gens such as hydroxyﬂutamide, ﬂutamide, bicalutamide, and
vincolozolin (Bauer et al., 1998; Gray et al., 1994; Kelce et al.,
1994; Waller et al., 1996; Wong et al., 1995). Vinclozolin is
converted in vivo into two metabolites, M1 and M2, with
higher antiandrogenic activity than the parent compound
(Kelce et al., 1994). The IC50 value of the parent compound
observed in the present study is in the range of the activity
reported by Wilson and coworkers (2002).
A complex situation was encountered with cyproterone
actetate (CPA). CPA was characterized by marked agonistic
activity across a wide concentration range when given alone, a
slight, nonsigniﬁcant tendency of DHT antagonism at low CPA
concentrations (0.1M), and an identical dose-response rela-
tionship at high CPA concentrations in the presence or absence
of DHT. CPA is known to possess signiﬁcant partial AR
agonist activity (Labrie et al., 1987). However, the failure by
hydroxyﬂutamide to reduce its agonistic effect speaks against
a major role of AR for the agonistic CPA action in the present
cell system. The effect might result from an action on the GR
expressed by MDA-kb2 cells; CPA has been reported to ex-
hibit glucocorticoid activity (Lamberts et al., 1988; Poulin et
al., 1991). A predominance of agonistic effects of CPA was
also observed in MCF7-AR1 cells expressing the human AR
(A-SCREEN assay) (Ma, 2002). Thus, antiandrogens with
mixed activities may present problems for analysis in both
assay systems.
As mentioned in the introduction, the use of UV ﬁlters has
greatly increased over the last decades. Since they are li-
pophilic, they may bioaccumulate in the food chain. Evidence
for this has been presented for ﬁsh (perch and roach in the
Meerfelder Maar lake, Germany; Nagtegaal et al., 1997), and
for human milk (Hany and Nagel, 1997). The presence in
human milk has recently been conﬁrmed for one UV ﬁlter in
this laboratory (unpublished observations). When analyzed for
potential endocrine activity, 4-MBC, OD-PABA, OMC, Bp-3,
and HMS exhibited estrogenic activity in vitro on MCF-7 cells
(increased proliferation, pS2 protein induction). 4-MBC, OMC,
and Bp-3 also increased uterine weight in immature rats
(Schlumpf et al., 2001). Two of these compounds, benzophe-
none- 3 (Bp-3) and homosalate (HMS), also showed signiﬁcant
androgen (DHT) antagonism in vitro in MDA-kb2 cells. Both
chemicals were completely devoid of agonistic actions when
tested alone. The IC50 values of the two UV ﬁlters were in the
low micromolar range, which is the effective range of other
environmental antiandrogenic chemicals such as vinclozolin
and linuron (Vinggaard et al., 1999; Wilson et al., 2002).
While in this cell line, HMS appeared only to antagonize
androgen actions and did not interfere with glucocorticoid
effects, high concentrations of Bp-3 elicited an unexpected
increase of luciferase activity in the presence of dexametha-
sone, beyond the level induced by the glucocorticoid. Since
hydroxyﬂutamide and the estrogen antagonist ICI 182,780
were unable to block this effect, its nature remains uncertain.
In conclusion, our investigation identiﬁed two out of eight
UV ﬁlters tested, Bp-3 and HMS, as antiandrogens in the in
vitro MDA-kb2 cell transcription assay. Both compounds also
act as estrogen agonists on MCF-7 cells in vitro, and Bp-3 is
estrogenic in the in vivo uterotrophic assay (Schlumpf et al.,
2001). In vitro estrogenic potencies (ED50 3.73 M for Bp-3
and 1.56 M for HMS) and antiandrogenic potencies (Table 2)
are in a similar range, but such comparisons should be done
with caution, considering the different endpoints of the two
assays (proliferation versus reporter gene). Our data support
the notion that some endocrine disrupting chemicals may in-
teract with endocrine regulation by more than one mechanism
(Sohoni et al., 1998). Whether Bp-3 and HMS are also AR
antagonists in vivo remains to be clariﬁed.
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